Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Kiyota H, Okamoto I, Takeda M, Daga H, Naito T, Miyazaki M, Okada H, Hayashi H, Tanaka K, Terashima M, Azuma K, Murakami H, Takeda K, Yamamoto N, Nakagawa K. Kiyota H, et al. Among authors: takeda k, takeda m. Cancer Chemother Pharmacol. 2013 Apr;71(4):859-65. doi: 10.1007/s00280-013-2077-1. Epub 2013 Jan 20. Cancer Chemother Pharmacol. 2013. PMID: 23334261 Clinical Trial.
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H. Nishiwaki Y, et al. Among authors: takeda k. Gan To Kagaku Ryoho. 2004 Apr;31(4):567-73. Gan To Kagaku Ryoho. 2004. PMID: 15114701 Clinical Trial. Japanese.
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Kudoh S, et al. Among authors: takeda k. J Clin Oncol. 2006 Aug 1;24(22):3657-63. doi: 10.1200/JCO.2006.06.1044. J Clin Oncol. 2006. PMID: 16877734 Clinical Trial.
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M. Tamura K, et al. Among authors: takeda k. Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. doi: 10.1007/s00280-006-0382-7. Epub 2006 Nov 30. Cancer Chemother Pharmacol. 2007. PMID: 17136542 Clinical Trial.
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
Takeda K, Takifuji N, Negoro S, Furuse K, Nakamura S, Takada Y, Hoso T, Hayasaka S, Nakano T, Araki J, Senba H, Iwami F, Yamaji Y, Fukuoka M, Ikegami H. Takeda K, et al. Invest New Drugs. 2007 Aug;25(4):377-83. doi: 10.1007/s10637-007-9039-6. Epub 2007 Mar 10. Invest New Drugs. 2007. PMID: 17351748 Clinical Trial.
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Nishimura Y, Nakagawa K, Takeda K, Tanaka M, Segawa Y, Tsujino K, Negoro S, Fuwa N, Hida T, Kawahara M, Katakami N, Hirokawa K, Yamamoto N, Fukuoka M, Ariyoshi Y. Nishimura Y, et al. Among authors: takeda k. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):786-92. doi: 10.1016/j.ijrobp.2007.04.008. Epub 2007 May 23. Int J Radiat Oncol Biol Phys. 2007. PMID: 17512126 Clinical Trial.
5,595 results